deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT02474667

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney

A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of ANG-3777 (Formerly BB3) to Improve Graft Function and Reduce the Severity of Kidney Dysfunction or Delayed Graft Function Following Kidney Transplantation in Recipients of a Deceased Donor Kidney

Sponsor: Angion Biomedica Corp

Conditions Delayed Graft Function
Interventions ANG-3777 Placebo
Updated 15 times since 2017 Last updated: Jun 1, 2021 Started: Mar 31, 2016 Primary completion: Sep 30, 2021 Completion: Sep 30, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Delayed Graft Function and is currently ongoing. Angion Biomedica Corp leads this study, which shows 15 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Sep 2019 · 15 months · monthly snapshot~Sep 2019 – ~Jan 2020 · 4 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~May 2023 · 20 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. May 2023 — Jul 2024 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  5. Sep 2021 — May 2023 [monthly]

    Active Not Recruiting PHASE3

▶ Show 10 earlier versions

  1. Mar 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  2. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  3. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  4. Feb 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  5. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE3

  6. Sep 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  7. Jun 2018 — Sep 2019 [monthly]

    Recruiting PHASE3

  8. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  9. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Angion Biomedica Corp
  • CTI Clinical Trial and Consulting Services
Data source: Angion Biomedica Corp

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Aurora, United States , Baltimore, United States , Charlottesville, United States , Chicago, United States , Cincinnati, United States , Columbus, United States , Evanston, United States , Houston, United States , Lawrence, United States and 17 more locations